Organoids and Organ-Chips
Stem-cell mini-organs and organ-chips test drugs on human tissue; in April 2025 the FDA announced a plan to phase out animal testing for some drugs.
Open in the interactive tree →In 2009 Hans Clevers' lab showed that single intestinal stem cells self-organise into gut-like structures in a dish, and in 2013 Madeline Lancaster grew brain-like cerebral organoids from pluripotent stem cells. Organoids lack blood vessels and stay immature, which limits their size and realism. On 10 April 2025 the FDA announced it would replace animal testing requirements for monoclonal antibodies and other drugs with human-relevant methods, naming lab-grown organoids, organ-on-a-chip systems and AI toxicity models.
As of October 2026
The FDA and NIH co-hosted a workshop on reducing animal research on 7 July 2025, and on 2 December 2025 FDA issued draft guidance on cutting the use of non-human primates in monoclonal-antibody toxicity studies. The FDA Modernization Act 3.0 (H.R. 2821), which would make FDA replace references to animal tests with language that includes non-animal methods within a year of enactment, passed the Senate in December 2025 and the House on 20 July 2026, and the Senate must still approve the House version. One expert quoted in March 2026 says the new methods work best in combination with animal studies rather than as complete replacements.
Open steps
- Proving chips predict human toxicity Medium AI leverageOne company's Liver-Chip met qualification criteria on 27 blinded drugs and sought FDA's final qualification in September 2026. Independent, multi-chip evidence is still missing.
- Batch variability and quality control Medium AI leverageOrganoids differ between batches and within a batch. Image-based models are being trained to grade quality and phenotype, but they generalise unevenly across batches.
- Blood vessels and maturity Medium AI leverageWithout blood vessels organoids stay small and immature. 3 mm liver organoids with vessel-like channels worked in mice in 2025; perfused, human-scale organs are still unsolved.
- Linked organs on chips Medium AI leverageSingle organs miss body-wide effects. Multi-organ chips, for example liver, muscle and heart, are being built, but standard benchmarks and workflows to adopt them are lacking.
Where AI could help
Medium AI leverage. AI toxicity models are part of the FDA roadmap, but organoid maturity and proof against human outcomes limit replacing animal data.
- Predict toxicity from organoid and organ-chip readouts
- Analyse organoid images and single-cell data at scale
- Find culture conditions that make organoids more mature
- Compare in-vitro results with clinical outcomes to validate methods
Shown so far
- The FDA's 10 April 2025 plan lists AI-based computational models of toxicity alongside organoids and organ-on-a-chip systems as human-relevant replacements for animal tests. source
Prerequisites
- Cell culture and HeLa cells1951Organoids extend cell culture from flat dishes to three-dimensional tissue
- Induced pluripotent stem cells2006